Journal
CLINICAL GENETICS
Volume 86, Issue 1, Pages 21-28Publisher
WILEY
DOI: 10.1111/cge.12392
Keywords
ADRs; adverse drug reactions; anthracycline; carbamazepine; cisplatin; codeine; pharmacogenomics; warfarin
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Child and Family Research Institute (CFRI)
- Michael Smith Foundation for Health Research
- CIHR-Drug Safety and Effectiveness Cross-Disciplinary Training Program
- Canada Foundation for Innovation
- Genome British Columbia
- CFRI
- University of British Columbia Faculty of Medicine
- Canadian Gene Cure Foundation
- C17 Research Network
- Childhood Cancer Foundation - Candlelighters Canada
Ask authors/readers for more resources
The vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available